RECOVERY · Injectable
TB-500.
System-wide tissue repair and recovery
How it works
Class & mechanism.
Class
Synthetic Peptide
Mechanism
TB-500 is a synthetic analogue of the active region of Thymosin Beta-4 (Tβ4), the body's main intracellular G-actin sequestering peptide. Its core mechanism is actin regulation: by binding G-actin, it controls cytoskeletal dynamics that govern how cells migrate to injury sites. This triggers a cascade of repair activity — fibroblast and endothelial cell migration to damaged tissue, upregulation of growth factors (TGF-β, FGF-2), promotion of angiogenesis via VEGF signalling, and modulation of inflammatory cell recruitment to favour resolution over chronic inflammation. Recent metabolomics research (Rahaman et al., 2024) suggests a key metabolite, Ac-LKKTE, may mediate much of its wound-healing activity.
Did you know
TB-500 is based on Thymosin Beta-4, a peptide so fundamental to cellular life that it's found in virtually every cell in the human body — and when researchers knock out its gene in mice, wounds that should heal in days instead never close at all.
Benefits
What it does.
Accelerated recovery from tendon, ligament, and muscle injuries — enhances myoblast migration to injury sites and improves neuromuscular junction regeneration
Reduced scarring and improved tissue remodelling — promotes matrix metalloproteinase expression and favours organised collagen deposition over fibrotic scar tissue
Anti-inflammatory without immunosuppression — modulates inflammatory cell recruitment patterns toward resolution, reducing chronic low-grade inflammation at injury sites
Cardiovascular and myocardial repair potential — preclinical porcine models show Tβ4 mediates cardioprotective effects of endothelial progenitor cells following myocardial infarction
Systemic flexibility and mobility improvement — athletes report reduced stiffness and improved range of motion in chronic injury sites, consistent with TB-500's actin-mediated cellular remodelling activity
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
A Phase 1 safety study in healthy volunteers found recombinant Thymosin Beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events reported
SOURCE · Wang et al., 2021 — Phase 1 clinical safety trial (cited in Dr. Jeffrey Peng MD clinical review, 2024)
In a clinically relevant porcine model of myocardial infarction, Tβ4 mediated significant cardioprotective effects via endothelial progenitor cells, demonstrating tissue-repair activity well beyond musculoskeletal applications
SOURCE · Peptide Biologix clinical monograph; translational porcine cardiac study
2024 metabolomics research identified that TB-500's wound-healing activity may primarily stem from its metabolite Ac-LKKTE rather than the parent compound itself — a finding that could inform more targeted next-generation formulations
SOURCE · Rahaman et al., 2024 — cited in Jeffrey Peng MD clinical review on TB-500
Protocol
How to use it.
Dosing
Loading phase: 4–6 mg per week split into 2–3 subcutaneous injections, typically for the first 4–6 weeks. Maintenance phase: 2–3 mg per week, once weekly or split into two doses. Injection near the site of injury is common practice, though subcutaneous abdominal injection is also used for systemic effect.
Cycle
Loading phase of 4–6 weeks followed by maintenance of 4–8 weeks. Standard cycling guidance: 3 months on, 6 weeks off for longer protocols. For acute injury recovery, a single 6–8 week loading cycle is common. Long-term use beyond 3 months without breaks is not recommended based on current clinical monographs.
Contraindications
When to skip it.
No FDA-approved dosing protocol for humans. Banned by WADA — prohibited in competitive sport. Theoretical concern around angiogenesis promotion in individuals with active cancers. A Phase 1 study confirmed short-term safety; long-term human data is absent. Physician supervision and cancer screening recommended before initiating any protocol.
Always cleared with your concierge before protocol start.
Pricing
What it costs.
Indicative range for TB-500, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See TB-500 pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $99–$149 USD